CY1118461T1 - Φαρμακευτικες συνθεσεις που περιλαμβανουν αναστολεα αρωματασης - Google Patents

Φαρμακευτικες συνθεσεις που περιλαμβανουν αναστολεα αρωματασης

Info

Publication number
CY1118461T1
CY1118461T1 CY20171100074T CY171100074T CY1118461T1 CY 1118461 T1 CY1118461 T1 CY 1118461T1 CY 20171100074 T CY20171100074 T CY 20171100074T CY 171100074 T CY171100074 T CY 171100074T CY 1118461 T1 CY1118461 T1 CY 1118461T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical compositions
aromatology
ingredients
compositions containing
relates
Prior art date
Application number
CY20171100074T
Other languages
English (en)
Inventor
Ann Taylor
Lloyd B Klickstein
Jeewan Thakur
Original Assignee
Mereo Biopharma 2 Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46846026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118461(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mereo Biopharma 2 Limited filed Critical Mereo Biopharma 2 Limited
Publication of CY1118461T1 publication Critical patent/CY1118461T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Abstract

Η παρούσα εφεύρεση αφορά σε χαμηλής-δόσης φαρμακευτικές συνθέσεις που περιλαμβάνουν τον αναστολέα αρωματάσης 4,4'-[φθορο-(1-Η-1,2,4-τριαζολ-1-υλ)μεθυλενο]δισβενζονιτρίλιο ως το δραστικό συστατικό σε κατάλληλο φορέα. Η παρούσα εφεύρεση επίσης αφορά σε μία μέθοδο για παρασκευή αυτού και χρήση αυτού ως φάρμακα.
CY20171100074T 2011-09-08 2017-01-18 Φαρμακευτικες συνθεσεις που περιλαμβανουν αναστολεα αρωματασης CY1118461T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161532459P 2011-09-08 2011-09-08
US201261638588P 2012-04-26 2012-04-26
PCT/US2012/053846 WO2013036563A1 (en) 2011-09-08 2012-09-06 Pharmaceutical compositions comprising an aromatase inhibitor

Publications (1)

Publication Number Publication Date
CY1118461T1 true CY1118461T1 (el) 2017-07-12

Family

ID=46846026

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100074T CY1118461T1 (el) 2011-09-08 2017-01-18 Φαρμακευτικες συνθεσεις που περιλαμβανουν αναστολεα αρωματασης
CY20171100100T CY1118499T1 (el) 2011-09-08 2017-01-24 Χρηση ενος αναστολεα αρωματασης για την αντιμετωπιση υπογοναδισμου και σχετικων νοσων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20171100100T CY1118499T1 (el) 2011-09-08 2017-01-24 Χρηση ενος αναστολεα αρωματασης για την αντιμετωπιση υπογοναδισμου και σχετικων νοσων

Country Status (30)

Country Link
US (4) US9295668B2 (el)
EP (2) EP2753313B1 (el)
JP (2) JP6280501B2 (el)
KR (3) KR20180030254A (el)
CN (2) CN103781476B (el)
AR (1) AR087790A1 (el)
AU (2) AU2012304694B2 (el)
BR (2) BR112014004879B1 (el)
CA (2) CA2846884C (el)
CL (1) CL2014000552A1 (el)
CY (2) CY1118461T1 (el)
DK (2) DK2753312T3 (el)
ES (2) ES2613666T3 (el)
HR (2) HRP20170003T1 (el)
HU (2) HUE031435T2 (el)
IL (1) IL231234A (el)
IN (1) IN2014DN01619A (el)
LT (2) LT2753312T (el)
MX (2) MX360315B (el)
PE (1) PE20141584A1 (el)
PL (2) PL2753312T3 (el)
PT (2) PT2753312T (el)
RU (2) RU2628808C2 (el)
SG (2) SG2014012132A (el)
SI (2) SI2753312T1 (el)
TN (1) TN2014000059A1 (el)
TW (1) TW201316987A (el)
UY (1) UY34315A (el)
WO (2) WO2013036562A1 (el)
ZA (1) ZA201401040B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2753312T3 (da) * 2011-09-08 2017-02-13 Mereo Biopharma 2 Ltd Anvendelse af en aromatase-inhibitor i behandlingen af hypogonadisme og relaterede sygdomme
WO2015148549A1 (en) * 2014-03-26 2015-10-01 The Regents Of The University Of California Ultrasensitive androgen receptor bioassay
EP3412278A1 (en) * 2014-07-07 2018-12-12 Novartis AG Pharmaceutical dosage forms
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
WO2018165145A1 (en) * 2017-03-08 2018-09-13 Ariad Pharmaceuticals, Inc. Pharmaceutical formulations comprising 5-chloro-n4-[2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl} pyrimidine-2,4-diamine
USD894149S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment
USD894148S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment
JP7121999B2 (ja) * 2019-09-26 2022-08-19 学校法人九州文化学園 男性性腺機能低下症治療剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749713A (en) * 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
TW210334B (el) * 1990-12-12 1993-08-01 Ciba Geigy Ag
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
WO2002002113A1 (en) * 2000-07-05 2002-01-10 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition
KR20040012751A (ko) 2001-04-17 2004-02-11 아레스 트레이딩 에스.에이. 보조 생식을 고양하기 위한 아로마타제 저해
US7101573B2 (en) 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
WO2003082254A1 (en) * 2002-04-03 2003-10-09 Jencap Research Ltd. Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
WO2006114702A2 (en) * 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
CN101868243A (zh) * 2007-11-21 2010-10-20 客乐谐制药株式会社 芳香酶抑制剂
DK2753312T3 (da) * 2011-09-08 2017-02-13 Mereo Biopharma 2 Ltd Anvendelse af en aromatase-inhibitor i behandlingen af hypogonadisme og relaterede sygdomme

Also Published As

Publication number Publication date
AR087790A1 (es) 2014-04-16
HRP20170002T1 (hr) 2017-02-24
WO2013036563A1 (en) 2013-03-14
CY1118499T1 (el) 2017-07-12
HUE031478T2 (hu) 2017-07-28
JP6280501B2 (ja) 2018-02-14
WO2013036562A1 (en) 2013-03-14
SI2753313T1 (sl) 2017-04-26
US20140213622A1 (en) 2014-07-31
PT2753312T (pt) 2017-02-03
IL231234A0 (en) 2014-04-30
TW201316987A (zh) 2013-05-01
ES2613667T3 (es) 2017-05-25
CN103796644A (zh) 2014-05-14
KR20180030254A (ko) 2018-03-21
PL2753313T3 (pl) 2017-07-31
BR112014004879A2 (pt) 2017-03-14
PL2753312T3 (pl) 2017-06-30
RU2014113334A (ru) 2015-10-20
BR112014005434A2 (pt) 2017-04-04
JP2014528932A (ja) 2014-10-30
KR101872561B1 (ko) 2018-06-28
CN103781476A (zh) 2014-05-07
HUE031435T2 (en) 2017-07-28
US20160346257A1 (en) 2016-12-01
CL2014000552A1 (es) 2014-09-12
BR112014004879B1 (pt) 2020-01-28
EP2753313B1 (en) 2016-12-14
CN103781476B (zh) 2016-12-07
US10064844B2 (en) 2018-09-04
EP2753312B1 (en) 2016-12-14
MX2014002773A (es) 2014-06-05
CA2846884C (en) 2019-04-09
BR112014005434B1 (pt) 2021-01-05
US9295668B2 (en) 2016-03-29
AU2012304693B2 (en) 2016-03-31
AU2012304694B2 (en) 2016-04-07
DK2753312T3 (da) 2017-02-13
RU2014113575A (ru) 2015-10-20
SG2014012132A (en) 2014-06-27
NZ621476A (en) 2016-02-26
HRP20170003T1 (hr) 2017-03-10
RU2617510C2 (ru) 2017-04-25
CA2846884A1 (en) 2013-03-14
CN103796644B (zh) 2017-05-03
TN2014000059A1 (en) 2015-07-01
US20160243084A1 (en) 2016-08-25
JP6051467B2 (ja) 2016-12-27
EP2753313A1 (en) 2014-07-16
PE20141584A1 (es) 2014-11-13
IN2014DN01619A (el) 2015-05-15
EP2753312A1 (en) 2014-07-16
IL231234A (en) 2016-12-29
US20140309267A1 (en) 2014-10-16
LT2753312T (lt) 2017-01-25
PT2753313T (pt) 2017-02-02
LT2753313T (lt) 2017-02-10
CA2845929C (en) 2018-06-19
UY34315A (es) 2013-04-30
RU2628808C2 (ru) 2017-08-22
SI2753312T1 (sl) 2017-10-30
CA2845929A1 (en) 2013-03-14
ES2613666T3 (es) 2017-05-25
US9750724B2 (en) 2017-09-05
JP2014526465A (ja) 2014-10-06
MX360315B (es) 2018-10-29
KR20140058619A (ko) 2014-05-14
MX2014002780A (es) 2014-06-05
ZA201401040B (en) 2015-12-23
SG10201607503WA (en) 2016-10-28
AU2012304694A1 (en) 2014-03-20
KR20140071358A (ko) 2014-06-11
MX343902B (es) 2016-11-28
AU2012304693A1 (en) 2014-03-13
US9370505B2 (en) 2016-06-21
DK2753313T3 (en) 2017-02-13

Similar Documents

Publication Publication Date Title
CY1118461T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν αναστολεα αρωματασης
CY1119435T1 (el) Σκευασμα για αντισωμα εναντι- αλφα4βητα7
CY1121373T1 (el) Μεθοδος και φαρμακοτεχνικη μορφη για εισπνοη
MX2018015892A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
TN2015000278A1 (en) Autotaxin inhibitors
TR201909461T4 (tr) Si̇stemi̇k olarak etki̇ eden akti̇f maddeleri̇ i̇çeren parazi̇ti̇si̇dal oral veteri̇nerli̇ğe ai̇t bi̇leşi̇mler, bunlarin yöntemleri̇ ve kullanimlari
GB2541835A (en) Multivesicular liposome formulations of tranexamic acid
MX346936B (es) Metodo, composiciones y empaque para limpieza del intestino.
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
TR200806298A2 (tr) Farmasötik formülasyon
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
WO2013104892A8 (en) Application of high dose compounds via inhalation
CY1113551T1 (el) Υποκατεστημενες ενωσεις νικοτιναμιδιου και η χρησιμοποιηση τους σε φαρμακα
CL2012002893A1 (es) Composición de al menos un ingrediente activo de origen vegetal o sintético análogo del mismo, o extracto de origen vegetal que lo contiene, en una solución acuosa, que además comprende lecitina como agente encapsulante; medicamento que la comprende; método para su preparación; y su uso para tratar parasitosis intestinales.
WO2013170086A3 (en) Formulations for the delivery of active ingredients
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
CY1115600T1 (el) Πιπεραζινες ως ανθελονοσιακοι παραγοντες
MX2014014579A (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
MY168692A (en) The treatment of viral infections
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
EA201491477A1 (ru) Фармацевтические составы, содержащие флупиртин
CR20120465A (es) Formulaciones mejoradas para ingredientes farmaceuticos activos de permeabilidad deficiente
CR11588A (es) Formulaciones farmacéuticas semisólidas
UA75916U (xx) Медичний перев'язувальний виріб